U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07383246) titled 'CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC' on Jan. 26.
Brief Summary: This is a multicenter, randomized, open-label, non-inferiority Phase III clinical trial, aims to compare 68Ga-CTR-FAPI PET-CT-guided surgery to investigator-chosen surgical approaches to evaluate its efficacy in treating newly diagnosed medullary thyroid carcinoma. This study plans to enroll 150 newly diagnosed MTC patients, who will be randomly assigned in a 2:1 ratio to the experimental group (surgery based on 68Ga-CTR-FAPI PET-CT findings) and the control group (surgery based on the investigator's choice). The primary endpoint is the biochemical ...